Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Other Operating Expenses (2019 - 2020)

Keros Therapeutics (KROS) has disclosed Other Operating Expenses for 2 consecutive years, with -$1.5 million as the latest value for Q1 2020.

  • For the quarter ending Q1 2020, Other Operating Expenses fell 146.69% year-over-year to -$1.5 million, compared with a TTM value of -$1.5 million through Dec 2020, up 41.89%, and an annual FY2020 reading of -$1.5 million, up 41.89% over the prior year.
  • Other Operating Expenses was -$1.5 million for Q1 2020 at Keros Therapeutics, down from -$78000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at -$78000.0 in Q4 2019 and bottomed at -$1.5 million in Q1 2020.